Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talsaclidine + propranolol
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Talsaclidine + propranolol** is an experimental combination of two small molecule drugs. **Talsaclidine** is a functionally preferential agonist of the muscarinic acetylcholine receptor M1, showing high intrinsic activity at M1 and less pronounced effects at M2 and M3 receptors. Its central cholinomimetic activation has been demonstrated to be dose-dependent, with side effects mainly mediated by muscarinic receptors. **Propranolol** is a non-selective beta-adrenergic receptor antagonist (beta-blocker) widely used in cardiovascular disease. The combination has been studied for effects on airway lumen, suggesting a research focus on their interplay affecting airway physiology, but not as a marketed or approved therapy. The developer identified in clinical trial context is Boehringer Ingelheim[1][2][3].
- Other names
- talsaclidinepropranolol
02
Targets
M1 (Muscarinic acetylcholine receptor M1)ADRB1 (β1)CHRM3 (M3)ADRB2 (β2)CHRM2 (M2)
Beyond the preview
Go deeper on talsaclidine + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talsaclidine + propranolol.